{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T08:37:52Z","timestamp":1774687072457,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,5,15]],"date-time":"2006-05-15T00:00:00Z","timestamp":1147651200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2006,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Cutaneous Leishmaniasis is a worldwide disease, endemic in 88 countries, that has shown an increasing incidence over the last two decades. So far, pentavalent antimony compounds have been considered the treatment of choice, with a percentage of cure of about 85%. However, the high efficacy of these drugs is counteracted by their many disadvantages and adverse events. Previous studies have shown nitric oxide to be a potential alternative treatment when administered topically with no serious adverse events. However, due to the unstable nitric oxide release, the topical donors needed to be applied frequently, making the adherence to the treatment difficult. The electrospinning technique has allowed the production of a multilayer transdermal patch that produces a continuous and stable nitric oxide release. The main objective of this study is to evaluate this novel nitric oxide topical donor for the treatment of cutaneous leishmaniasis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and design<\/jats:title><jats:p>A double-blind, randomized, double-masked, placebo-controlled clinical trial, including 620 patients from endemic areas for Leishmaniasis in Colombia was designed to investigate whether this patch is as effective as meglumine antimoniate for the treatment of cutaneous leishmaniasis but with less adverse events. Subjects with ulcers characteristic of cutaneous leishmaniasis will be medically evaluated and laboratory tests and parasitological confirmation performed. After checking the inclusion\/exclusion criteria, the patients will be randomly assigned to one of two groups. During 20 days Group 1 will receive simultaneously meglumine antimoniate and placebo of nitric oxide patches while Group 2 will receive placebo of meglumine antimoniate and active nitric oxide patches. During the treatment visits, the medications will be daily administered and the presence of adverse events assessed. During the follow-up, the research group will visit the patients at days 21, 45, 90 and 180. The healing process of the ulcer, the health of the participants, recidivisms and\/or reinfection will also be assessed. The evolution of the ulcers will be photographically registered. In case that the effectiveness of the patches is demonstrated, a novel and safe therapeutic alternative for one of the most important public health problems in many countries will be available to patients.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1745-6215-7-14","type":"journal-article","created":{"date-parts":[[2006,5,16]],"date-time":"2006-05-16T07:09:19Z","timestamp":1147763359000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Double blind, randomized controlled trial, to evaluate the effectiveness of a controlled nitric oxide releasing patch versus meglumine antimoniate in the treatment of cutaneous leishmaniasis [NCT00317629]"],"prefix":"10.1186","volume":"7","author":[{"given":"Sandra Y","family":"Silva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ligia C","family":"Rueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iv\u00e1n D","family":"V\u00e9lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian F","family":"Rueda-Clausen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerardo","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hernando","family":"Mosquera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico A","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Buitrago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricio","family":"L\u00f3pez-Jaramillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,5,15]]},"reference":[{"key":"151_CR1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4103\/0022-3859.927","volume":"49","author":"S S","year":"2003","unstructured":"S S, R S: Recent Advance in the diagnosis of Leishmaniasis. J Postgrad Med. 2003, 49: 55-60.","journal-title":"J Postgrad Med"},{"key":"151_CR2","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/0738-081X(96)00057-0","volume":"14","author":"D P","year":"1996","unstructured":"P D: Leishmaniasis: Public health aspects and control. Clin Dermatol. 1996, 14: 417-413. 10.1016\/0738-081X(96)00057-0.","journal-title":"Clin Dermatol"},{"key":"151_CR3","volume-title":"Principles and practice of infection diseases","author":"Mandell","year":"2000","unstructured":"Mandell: Principles and practice of infection diseases. Edited by: Elsevier . 2000, Churchill Livingstone, Inc., 5","edition":"5"},{"key":"151_CR4","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/S0140-6736(98)10178-2","volume":"354","author":"H BL","year":"1999","unstructured":"BL H: Leishmaniasis. Lancet. 1999, 354: 1191-1199. 10.1016\/S0140-6736(98)10178-2.","journal-title":"Lancet"},{"key":"151_CR5","first-page":"73","volume":"7","author":"A RW","year":"1992","unstructured":"RW A, P D, P R: Estimation of population at risk of infection and number of cases of Leishmaniasis. Parasitology Today. 1992, 7: 73-107.","journal-title":"Parasitology Today"},{"key":"151_CR6","unstructured":"Update: Cutaneous leishmaniasis in U.S. military personnel--Southwest\/Central Asia, 2002-2004. MMWR Morb Mortal Wkly Rep. 2004, 53: 264-265."},{"key":"151_CR7","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1590\/S0102-311X2000000400013","volume":"16","author":"D CR","year":"2000","unstructured":"CR D, R R, D CL, D F, R B, N R: The epidemiology and control of Leishmaniasis in Andean countries. Cad Saude Publica. 2000, 16: 925-950.","journal-title":"Cad Saude Publica"},{"key":"151_CR8","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1590\/S0074-02762002000500008","volume":"97","author":"A LA","year":"2002","unstructured":"LA A, J U, D S, F R, ID V: Presence of American cutaneous Leishmaniasis vectors surrounding the city of Medell\u00edn, Colombia. Mem Inst Oswaldo Cruz. 2002, 97: 641-642.","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"151_CR9","doi-asserted-by":"crossref","first-page":"86","DOI":"10.4269\/ajtmh.1998.59.86","volume":"59","author":"S NG","year":"1998","unstructured":"NG S, I S, AF H, C S, L V, C O: Epidemiologic, genetic, and clinical associations among phenotypically distinct populations of Leishmania (Viannia) in Colombia. Am J Trop Med Hyg. 1998, 59: 86-94.","journal-title":"Am J Trop Med Hyg"},{"key":"151_CR10","first-page":"1455","volume":"69","author":"M W","year":"2004","unstructured":"W M, K M: Cutaneous Leishmaniasis: Recognition and treatment. Am Fam Physician. 2004, 69: 1455-1460.","journal-title":"Am Fam Physician"},{"key":"151_CR11","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1136\/bmj.321.7264.801","volume":"321","author":"R L","year":"2000","unstructured":"L R, E H, S F: Leishmaniasis. BMJ. 2000, 321: 801-804. 10.1136\/bmj.321.7264.801.","journal-title":"BMJ"},{"key":"151_CR12","volume-title":"Biomedica","author":"M G","year":"2006","unstructured":"G M, C D: Leishmania panamensis transmission in the domestic environment: the results of a prospective epidemiological survey in Santander, Colombia. Biomedica. 2006, In press:"},{"key":"151_CR13","doi-asserted-by":"publisher","first-page":"50","DOI":"10.4103\/0022-3859.928","volume":"49","author":"H NC","year":"2003","unstructured":"NC H: Cutaneous Leishmaniasis: an overview. J Postgrad Med. 2003, 49: 50-54.","journal-title":"J Postgrad Med"},{"key":"151_CR14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1365-2133.1993.tb00149.x","volume":"128","author":"H NC","year":"1993","unstructured":"NC H, MJ T, JA H: Cutaneous Leishmaniasis in British troops from Belize. Br J Dermatol. 1993, 128: 63-68.","journal-title":"Br J Dermatol"},{"key":"151_CR15","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1093\/infdis\/165.3.518","volume":"165","author":"H BL","year":"1992","unstructured":"BL H, BA A, TR N: The natural history of cutaneous Leishmaniasis in Guatemala. J Infect Dis. 1992, 165: 518-527.","journal-title":"J Infect Dis"},{"key":"151_CR16","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4269\/ajtmh.1998.59.49","volume":"59","author":"O LE","year":"1998","unstructured":"LE O, MC C, MT O: Mucosal Leishmaniasis due to Leishmania (viannia)panamensis in Colombia: clinical characteristics. Am J Trop Med Hyg. 1998, 59: 49-52.","journal-title":"Am J Trop Med Hyg"},{"key":"151_CR17","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4269\/ajtmh.2001.64.187","volume":"64","author":"P R","year":"2001","unstructured":"R P, LE O, LF G, MT O: Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous Leishmaniasis due to Leishmaniaviannia species. Am J Trop Med Hyg. 2001, 64: 187-193.","journal-title":"Am J Trop Med Hyg"},{"key":"151_CR18","doi-asserted-by":"crossref","first-page":"296","DOI":"10.4269\/ajtmh.1992.46.296","volume":"46","author":"H BL","year":"1992","unstructured":"BL H, JD B: Recommendations for treating Leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg. 1992, 46: 296-306.","journal-title":"Am J Trop Med Hyg"},{"key":"151_CR19","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1093\/jac\/dkh058","volume":"53","author":"B J","year":"2004","unstructured":"J B, P D, E S, B B, C H: Treatment of cutaneous Leishmaniasis among travelers. J Antimicrob Chemother. 2004, 53: 158-166. 10.1093\/jac\/dkh058.","journal-title":"J Antimicrob Chemother"},{"key":"151_CR20","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1086\/516267","volume":"26","author":"S J","year":"1998","unstructured":"J S, P F, R H, J B: Topical paromomycin\/methylbenzethonium chloride plus parenteral meglumine antimotiate as treatment for american cutaneos leishmaniasis: Controlled Study. Clin Infect Disease. 1998, 26: 56-58.","journal-title":"Clin Infect Disease"},{"key":"151_CR21","doi-asserted-by":"crossref","first-page":"889","DOI":"10.4269\/ajtmh.1998.59.889","volume":"59","author":"H EP","year":"1998","unstructured":"EP H, SP A, DL M, JA P, ID V: Lack of efficacy of mefloquine in the treatment of new world cutaneous leishmaniasis in colombia. Am J Trop Med Hyg. 1998, 59: 889-892.","journal-title":"Am J Trop Med Hyg"},{"key":"151_CR22","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/clind\/24.4.684","volume":"24","author":"B JD","year":"1997","unstructured":"JD B: Leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis. 1997, 24: 684-703.","journal-title":"Clin Infect Dis"},{"key":"151_CR23","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S1695-4033(03)78776-1","volume":"59","author":"F MC","year":"2003","unstructured":"MC F, MJ GM, F A, BR V, A C, AI A: Tratamiento de corta duraci\u00f3n de la Leishmaniasis visceral con anfotericina B lipos\u00f3mica en pacientes inmunocompetentes. An Pediatr (Barc). 2003, 59: 535-540. 10.1157\/13054334.","journal-title":"An Pediatr (Barc)"},{"key":"151_CR24","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1093\/qjmed\/92.11.659","volume":"92","author":"S RA","year":"1999","unstructured":"RA S, J M, I M, J W, D N: Out-patient parenteral antimicrobial therapy-a viable option for the management of cutaneous Leishmaniasis. QJM. 1999, 92: 659-667. 10.1093\/qjmed\/92.11.659.","journal-title":"QJM"},{"key":"151_CR25","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/0035-9203(94)90235-6","volume":"88","author":"S J","year":"1994","unstructured":"J S, M G, J B, P O: Limited efficacy of injectable aminosidine as single-agent therapy for Colombian cutaneous Leishmaniasis. Trans R Soc Trop Med Hyg. 1994, 88: 695-698. 10.1016\/0035-9203(94)90235-6.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"151_CR26","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1086\/383321","volume":"38","author":"S J","year":"2004","unstructured":"J S, BA A, J T, N R, JC V, A D, P G, M A, JD B, K J, J E, H S: Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis. 2004, 38: 1266-1272. 10.1086\/383321.","journal-title":"Clin Infect Dis"},{"key":"151_CR27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.4269\/ajtmh.2002.66.147","volume":"66","author":"S J","year":"2002","unstructured":"J S, J T, P G, M A, RS N, JR P, JD B, CK E, M G: Treatment of cutaneous Leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study. J Trop Med Hyg. 2002, 66: 147-152.","journal-title":"J Trop Med Hyg"},{"key":"151_CR28","doi-asserted-by":"crossref","first-page":"648","DOI":"10.4269\/ajtmh.1995.53.648","volume":"53","author":"A A","year":"1995","unstructured":"A A, T J, JA W, RL G, M N, P O: A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous Leishmaniasis in Iran. Am J Trop Med Hyg. 1995, 53: 648-651.","journal-title":"Am J Trop Med Hyg"},{"key":"151_CR29","doi-asserted-by":"publisher","first-page":"33883","DOI":"10.1074\/jbc.M003671200","volume":"275","author":"M MA","year":"2000","unstructured":"MA M, SE MG, KR G, M C, SL N, KA A, CJ B, N Y, BE B, ME W: Inducible resistance to oxidant stress in the protozoan Leishmaniachagasi. J Biol Chem. 2000, 275: 33883-33889. 10.1074\/jbc.M003671200.","journal-title":"J Biol Chem"},{"key":"151_CR30","first-page":"1","volume":"68","author":"K M","year":"1997","unstructured":"M K: Regulator and effector functions of T-cell subsets in human Leishmania infections. APMIS. 1997, 68: 1-33.","journal-title":"APMIS"},{"key":"151_CR31","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1126\/science.284.5416.951","volume":"284","author":"D A","year":"1999","unstructured":"A D, H S, M R, WM Y, C B: Requirement for type 2 NO synthase for IL-12 signaling in innate immunity. Science. 1999, 284: 951-955. 10.1126\/science.284.5416.951.","journal-title":"Science"},{"key":"151_CR32","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1046\/j.1365-2230.2003.01206.x","volume":"28","author":"D NL","year":"2003","unstructured":"NL D, M F, E F, R R, IB M, FJ T: Nitric oxide and cellular immunity in experimental cutaneous Leishmaniasis. Clin Exp Dermatol. 2003, 28: 288-263. 10.1046\/j.1365-2230.2003.01206.x.","journal-title":"Clin Exp Dermatol"},{"key":"151_CR33","doi-asserted-by":"publisher","first-page":"893","DOI":"10.4049\/jimmunol.167.2.893","volume":"167","author":"G K","year":"2001","unstructured":"K G, TL G, ML MC, MA M, S J, BE B, ME W: Oxidative Responses of Human and Murine Macrophages During Phagocytosis of Leishmania chagasi. J of Immunol. 2001, 167: 893-901.","journal-title":"J of Immunol"},{"key":"151_CR34","doi-asserted-by":"publisher","first-page":"4638","DOI":"10.1128\/IAI.70.8.4638-4642.2002","volume":"70","author":"Q M","year":"2002","unstructured":"M Q, I B, N D, M R, C B: Expression of inducible nitric oxide synthase in skin lesions of patients with american cutaneous Leishmaniasis. Infect Immun. 2002, 70: 4638-4642. 10.1128\/IAI.70.8.4638-4642.2002.","journal-title":"Infect Immun"},{"key":"151_CR35","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.4049\/jimmunol.144.12.4794","volume":"144","author":"L FY","year":"1990","unstructured":"FY L, S M, C P, RM P, S M: Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J Immunol. 1990, 144: 4794-4797.","journal-title":"J Immunol"},{"key":"151_CR36","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1056\/NEJM199312303292706","volume":"329","author":"S Moncada","year":"1993","unstructured":"Moncada S, Higgs A: The L-arginine-nitric oxide pathway. N Engl J Med. 1993, 329: 2002-2012. 10.1056\/NEJM199312303292706.","journal-title":"N Engl J Med"},{"key":"151_CR37","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/eji.1830270409","volume":"27","author":"V I","year":"1997","unstructured":"I V, PA B, V RM, M A, O S, P D, D M, MD M: Interleukin-10 and interleukin-4 inhibit intracellular killing of Leishmania infantum and Leishmania major by human macrophages by decreasing nitric oxide generation. Eur J Immunol. 1997, 27: 860-865.","journal-title":"Eur J Immunol"},{"key":"151_CR38","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/eji.1830250318","volume":"25","author":"P L","year":"1995","unstructured":"L P, CA OD, FY L: Glycoinositolphospholipids of Leishmania major inhibit nitric oxide synthesis and reduce leishmanicidal activity in murine macrophages. Eur J Immunol. 1995, 25: 745-750.","journal-title":"Eur J Immunol"},{"key":"151_CR39","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/S0140-6736(05)79119-4","volume":"351","author":"LJ P","year":"1998","unstructured":"P LJ, C R, J R, E T, R SI, JV E, S M: Treatment of cutaneous Leishmaniasis with nitric-oxide donor. Lancet. 1998, 351: 1176-1177. 10.1016\/S0140-6736(05)79119-4.","journal-title":"Lancet"},{"key":"151_CR40","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0035-9203(00)90341-9","volume":"94","author":"D RN","year":"2000","unstructured":"RN D, V Y, SL C, P K, N B: A topical nitric oxide-generating therapy for cutaneous Leishmaniasis. Trans R Soc Trop Med Hyg. 2000, 94: 319-322. 10.1016\/S0035-9203(00)90341-9.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"151_CR41","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/0304-3886(95)00041-8","volume":"35","author":"D J","year":"1995","unstructured":"J D, DH R: Electrospinning process and applications of electrospun fibers. J of Electrostatics. 1995, 35: 151-160. 10.1016\/0304-3886(95)00041-8.","journal-title":"J of Electrostatics"},{"key":"151_CR42","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/S0142-9612(02)00422-2","volume":"24","author":"ER Kenawy","year":"2003","unstructured":"Kenawy ER, J L, JR W, GL B, JA M, DG S, GE W: Electrospinning of poly(ethylene-co-vinyl alcohol) fibers. Biomaterials. 2003, 24: 907-913. 10.1016\/S0142-9612(02)00422-2.","journal-title":"Biomaterials"},{"key":"151_CR43","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0168-3659(02)00041-X","volume":"81","author":"ER Kenawy","year":"2002","unstructured":"Kenawy ER, GL B, K M, J L, DG S, EH S, GE W: Release of tetracycline hydrochloride from electrospun poly(ethylene-co-vinylacetate), poly(lactic acid), and a blend. J Control Release. 2002, 81: 57-64. 10.1016\/S0168-3659(02)00041-X.","journal-title":"J Control Release"},{"key":"151_CR44","first-page":"508","volume":"90","author":"H LM","year":"2004","unstructured":"LM H, W K, DH R, DJ S: Production of superabsorbent electrospun nanofibers. Polymeric Materials Science and Engineering. 2004, 90: 508-","journal-title":"Polymeric Materials Science and Engineering"},{"key":"151_CR45","volume-title":"PCT Int Appl WO 2004-US23867","author":"S D","year":"2004","unstructured":"D S: Stabilization and ionic triggering of nitric oxide release. PCT Int Appl WO 2004-US23867. 2004"},{"key":"151_CR46","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/00001432-200304000-00006","volume":"16","author":"F Vega-Lopez","year":"2003","unstructured":"Vega-Lopez F: Diagnosis of cutaneous leishmaniasis. Curr Opin Infect Dis. 2003, 16: 97-101.","journal-title":"Curr Opin Infect Dis"},{"key":"151_CR47","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/S0195-5616(89)50107-4","volume":"19","author":"WJ Foreyt","year":"1989","unstructured":"Foreyt WJ: Diagnostic parasitology. Vet Clin North Am Small Anim Pract. 1989, 19: 979-1000.","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"151_CR48","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3109\/10408419509113537","volume":"21","author":"K Kar","year":"1995","unstructured":"Kar K: Serodiagnosis of leishmaniasis. Crit Rev Microbiol. 1995, 21: 123-152.","journal-title":"Crit Rev Microbiol"},{"key":"151_CR49","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1590\/S0074-02761996000100006","volume":"91","author":"G Grimaldi","year":"1996","unstructured":"Grimaldi G, McMahon-Pratt D: Monoclonal antibodies for the identification of New World Leishmania species. Mem Inst Oswaldo Cruz. 1996, 91: 37-42.","journal-title":"Mem Inst Oswaldo Cruz"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1745-6215-7-14.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1745-6215-7-14\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1745-6215-7-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1745-6215-7-14.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,7]],"date-time":"2023-05-07T12:39:22Z","timestamp":1683463162000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/1745-6215-7-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,15]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["151"],"URL":"https:\/\/doi.org\/10.1186\/1745-6215-7-14","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,5,15]]},"assertion":[{"value":"27 April 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2006","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2006","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"14"}}